H.C. Wainwright Thinks Organovo Holdings’ Stock is Going to Recover


In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Organovo Holdings (ONVO), with a price target of $2.50. The company’s shares closed yesterday at $0.99, close to its 52-week low of $0.90.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.9% and a 37.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.

Organovo Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $2.75.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.09 and a one-year low of $0.90. Currently, Organovo Holdings has an average volume of 545.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Organovo Holdings, Inc. is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo Holdings was founded on January 30, 2012 and is headquartered in San Diego, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts